Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris shares the inspiring journey of Matt Klein, its senior director of global corporate communications, who began running marathons after being inspired by his sister in 2004. Since then, he has completed over 70 marathons and aims to run in all 50 U.S. states.

After the loss of his father in 2018, he took on a 200-mile run to honor him and has participated in three 200-mile races within four months. Klein has raised over $100,000 for charity through his running endeavors, highlighting the importance of community and resilience.

Viatris Inc. (NASDAQ:VTRS) announced a $1 million donation to enhance global access to healthcare, food security, and water stewardship. The funds are allocated to four organizations: Direct Relief, World Central Kitchen, WaterAid, and World Food Program USA. Each organization will receive $250,000 to address pressing global challenges, including the impacts of COVID-19, climate change, and food insecurity. This initiative aligns with Viatris' commitment to the UN Global Compact and Sustainable Development Goals, emphasizing the role of businesses in fostering solutions to societal issues.

Viatris (NASDAQ: VTRS) has completed its acquisitions of Oyster Point Pharma and Famy Life Sciences, forming a new Eye Care Division. The total acquisition prices were approximately $415 million for Oyster Point Pharma and $280 million for Famy Life Sciences, with both transactions anticipated to generate at least $1 billion in sales by 2028. The new division aims to leverage combined expertise to enhance patient access and solidify Viatris' position in the global eye care market.

Viatris Inc. (NASDAQ: VTRS) has appointed Scott A. Smith and Elisha W. Finney to its board of directors, succeeding retiring members Neil Dimick and Ian Read. Scott Smith, formerly President at Celgene, brings extensive experience in the biotechnology sector, while Finney has a strong financial background from her tenure at Varian Medical Systems. Both new directors are expected to enhance Viatris' strategy for growth and innovation in the pharmaceutical sector. The changes come as the company prepares to advance to its second phase post-Combination in November 2020.

Viatris Inc. (NASDAQ: VTRS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, in San Francisco. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will represent the company. A presentation followed by a fireside chat is scheduled for 3 p.m. PST / 6 p.m. EST. Interested parties can access a live webcast at investor.viatris.com, with an archived version available later. Viatris empowers global health through access to medicines and innovative solutions.

On December 14, 2022, Viatris (NASDAQ: VTRS) announced a $1 million donation to enhance healthcare access, food security, and water stewardship worldwide. The contributions, allocated evenly to Direct Relief, World Central Kitchen, WaterAid, and World Food Program USA, align with the company's commitment to the UN Sustainable Development Goals. CEO Michael Goettler emphasized the importance of addressing global challenges such as the COVID-19 pandemic, climate change, and access disparities. This initiative reflects Viatris' mission to empower global health and well-being.

On December 14, 2022, Viatris Inc. (NASDAQ: VTRS) announced that its emissions reduction targets received approval from the Science Based Targets initiative (SBTi). The company aims to reduce absolute scope 1 and 2 greenhouse gas emissions by 42% by 2030, from a 2020 baseline, and absolute scope 3 emissions by 25% in the same timeframe. Viatris emphasized its commitment to sustainability, aligning its operations with climate science while ensuring reliable medicine supply. This initiative is part of Viatris' broader sustainability goals established earlier this year.

Viatris Inc. (NASDAQ: VTRS) has finalized its deal with Biocon Biologics, receiving a $2 billion cash payment and $1 billion in convertible preferred equity, amounting to a 12.9% stake in Biocon Biologics. This transaction marks a strategic move towards becoming a global leader in biosimilars. Financial forecasts suggest a decline of $80 million in revenues and $20 million in adjusted EBITDA for the year ending December 31, 2022, due to the transaction costs of approximately $400 million. The company plans to use proceeds to reduce debt and fund acquisitions.